Patents Examined by Yih-Horng Shiao
  • Patent number: 12129255
    Abstract: The compound and pharmaceutically acceptable salts thereof, and compositions and methods for treating human immunodeficiency virus (HIV) infection are set forth.
    Type: Grant
    Filed: June 17, 2020
    Date of Patent: October 29, 2024
    Assignee: ViiV Healthcare UK (No. 5) Limited
    Inventors: Eric P. Gillis, Christiana Iwuagwu
  • Patent number: 12129460
    Abstract: Provided herein are methods of purifying messenger RNA (mRNA) by subjecting a preparation comprising in vitro synthesized mRNA to one or more steps of enzymatic digestion with a proteinase, optionally with a further oligo dT affinity chromatography step. Also provided are mRNA purified by the methods described herein.
    Type: Grant
    Filed: July 28, 2023
    Date of Patent: October 29, 2024
    Assignee: SANOFI
    Inventors: Eric Calvosa, Nicolas Chaudet, Arthur Leclercq, Alban Lepetitcolin
  • Patent number: 12128105
    Abstract: The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-?1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and/or ameliorating heart failure in a subject when administered in therapeutically effective amounts.
    Type: Grant
    Filed: March 8, 2023
    Date of Patent: October 29, 2024
    Assignee: Yale University
    Inventors: David Caianiello, Edward Deramon, David Spiegel
  • Patent number: 12128095
    Abstract: In one aspect, the invention relates to an immunogenic composition comprising modified O-polysaccharide molecules derived from E. coli lipopolysaccharides and conjugates thereof. Multivalent vaccines may be prepared by combining two or more monovalent immunogenic compositions for different E. coli serotypes. In one embodiment, the modified O-polysaccharide molecules are produced by a recombinant bacterium that includes a wzz gene.
    Type: Grant
    Filed: February 15, 2022
    Date of Patent: October 29, 2024
    Assignee: Pfizer Inc.
    Inventors: Robert G. K. Donald, Annaliesa Sybil Anderson, Laurent Oliver Chorro, Jianxin Gu, Jin-Hwan Kim, Srinivas Kodali, Jason Arnold Lotvin, Justin Keith Moran, Rosalind Pan, Avvari Krishna Prasad, Mark Edward Ruppen, Suddham Singh, Ling Chu, Scott Ellis Lomberk, Karen Kiyoko Takane, Nishith Merchant, Wei Chen
  • Patent number: 12128059
    Abstract: The disclosure provides a topical gel formulation comprising 1-1.5 wt. % clindamycin phosphate, 2.5-3.5 wt. % benzoyl peroxide, and 0.1-0.2 wt. % adapalene, in combination with a gelling agent, a polyhydric alcohol, and water, useful in treating inflammatory skin conditions, including acne, together with methods of making and using the same.
    Type: Grant
    Filed: June 8, 2022
    Date of Patent: October 29, 2024
    Assignee: BAUSCH HEALTH IRELAND LIMITED
    Inventors: Varsha Bhatt, Radhakrishnan Pillai, Arturo Angel
  • Patent number: 12128091
    Abstract: A food supplement is disclosed that comprises an extracellular matrix composition of hydrolyzed collagen, hyaluronic acid and glucosamine, ascorbic acid and, optionally, a cannabinoid composition. The food supplement can be given to pet animals for the relief of or prophylaxis of degenerative joint diseases, such as arthritis.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: October 29, 2024
    Assignee: PAW POWER, INC.
    Inventor: Anja Skodda
  • Patent number: 12121042
    Abstract: Dispersion type feed additive compositions for ruminants, containing (A) at least one selected from hydrogenated vegetable oil and hydrogenated animal oil each having a melting point of higher than 50° C. and lower than 90° C., (B) not less than 0.01 wt % and not more than 6 wt % of a surfactant, (C) not less than 16 wt % and not more than 72 wt % of a biologically active substance (excluding L-lysine and a salt thereof), and (D) not less than 1 wt % and not more than 40 wt % of L-lysine or a salt thereof, contain a biologically active substance at a high concentration, show high protection in the rumen, and are also superior in dissolution in the intestinal tract.
    Type: Grant
    Filed: December 29, 2022
    Date of Patent: October 22, 2024
    Assignee: AJINOMOTO CO., INC.
    Inventors: Sachiko Yonemaru, Koji Haga, Yuki Miyazawa, Susumu Shibahara
  • Patent number: 12115150
    Abstract: The disclosure is directed to ABC294640, as free base or as salts thereof, in preparing medicines for treating coronavirus infection or preventing diseases caused by coronavirus infection, and a medicine for preventing coronavirus infection or preventing diseases caused by coronavirus infection.
    Type: Grant
    Filed: August 31, 2022
    Date of Patent: October 15, 2024
    Assignee: RedHill Biopharma Ltd.
    Inventors: Dror Ben-Asher, Reza Fathi, Mark Levitt, Ofra Barnett
  • Patent number: 12115178
    Abstract: Disclosed herein are acylated active agents and methods of their use, e.g., for modulating an autoimmunity marker or for treating an autoimmune disorder.
    Type: Grant
    Filed: December 21, 2021
    Date of Patent: October 15, 2024
    Assignee: Flagship Pioneering Innovations V, Inc.
    Inventors: Steven John Taylor, Mi-Jeong Kim, Kathleen Nudel, Timothy F. Briggs, Koji Yasuda, Leonard Buckbinder, Bernard Lanter, Spencer Cory Peck, Cheri Snedeker, Angela She, Jessica Alexander, Anna Liang, Jenny Liu, Dinara Gunasekera, David Arthur Berry, John Patrick Casey, Jr., Amir H. Moarefi
  • Patent number: 12116573
    Abstract: Described are novel targeting ligands that may be linked to compounds, such therapeutic compounds, that are useful in directing the compounds to the target in vivo. The targeting ligands disclosed herein can serve to target expression-inhibiting oligomeric compounds, such as RNAi agents, to liver cells to modulate gene expression. The targeting ligands disclosed herein, when conjugated to an expression-inhibiting oligomeric compound, may be used in a variety of applications, including use in therapeutic, diagnostic, target validation, and genomic discovery applications. Compositions including the targeting ligands disclosed herein when linked to expression-inhibiting oligomeric compounds are capable of mediating expression of target nucleic acid sequences in liver cells, such as hepatocytes, which may be useful in the treatment of diseases or conditions that respond to inhibition of gene expression or activity in a cell, tissue, or organism.
    Type: Grant
    Filed: February 24, 2021
    Date of Patent: October 15, 2024
    Assignee: Arrowhead Pharmaceuticals, Inc.
    Inventors: David B. Rozema, Darren H. Wakefield, Andrei V. Blokhin, Jonathan D. Benson, Zhen Li, Tao Pei, Fred Fleitz
  • Patent number: 12110347
    Abstract: An enzymatically produced soluble ?-glucan fiber composition is provided suitable for use as a digestion resistant fiber in food and feed applications. The soluble ?-glucan fiber composition can be blended with one or more additional food ingredients to produce fiber-containing compositions. Methods for the production and use of compositions comprising the soluble ?-glucan fiber are also provided.
    Type: Grant
    Filed: February 25, 2022
    Date of Patent: October 8, 2024
    Assignee: NUTRITION & BIOSCIENCES USA 4, INC.
    Inventors: Qiong Cheng, Robert DiCosimo, Arthur Ouwehand, Zheng You, Mark S. Payne, Jian Ping Lai, Kristin Ruebling-Jass, Steven Cary Rothman
  • Patent number: 12102089
    Abstract: The invention relates to inactivating mold spores in a beverage using pasteurization in the presence of natamycin and to a beverage comprising natamycin and mycosamine.
    Type: Grant
    Filed: October 21, 2022
    Date of Patent: October 1, 2024
    Assignee: DSM IP ASSETS B.V.
    Inventors: Ben Rudolf De Haan, Angelina Dekker
  • Patent number: 12083116
    Abstract: The present invention discloses a method to recover and restore dendritic and synaptic neuron connections that have been degraded or destroyed by neurodegenerative diseases. In the present invention tryptamines are used to induce neuro plasticity and restore both dendritic density and synaptic connections of neurons in the brain. In the preferred embodiment LSD given in micro doses can induce dendritic and synaptic genesis in neuronal networks and improve the quality of life of people with neurodegenerative diseases such as Alzheimer's, Huntington's, Multiple Sclerosis, Parkinson's and Frontotemporal dementia.
    Type: Grant
    Filed: June 21, 2019
    Date of Patent: September 10, 2024
    Inventor: Robert John Petcavich
  • Patent number: 12083140
    Abstract: A pharmaceutical composition for preventing or treating eye diseases and an oral administration agent for preventing or treating eye diseases are provided, wherein the pharmaceutical composition for preventing or treating eye diseases includes the compound represented by Chemical Formula 1 or a pharmaceutically acceptable salt thereof as an active ingredient.
    Type: Grant
    Filed: August 26, 2021
    Date of Patent: September 10, 2024
    Assignee: FUTURE MEDICINE CO., LTD.
    Inventors: Sang Koo Lee, Chong Woo Park, Hea Ok Kim, Hee Woo Lee, Mi Ra Yu
  • Patent number: 12076407
    Abstract: Compounds useful as biologically active compounds are disclosed. The compounds have the following structure (I): or a stereoisomer, tautomer or salt thereof, wherein A, R1, R2, R3, R4, R5, L, L1, L2, L3, L4, M, m and n are as defined herein. Methods associated with preparation and use of such compounds is also provided.
    Type: Grant
    Filed: January 11, 2019
    Date of Patent: September 3, 2024
    Assignee: SONY GROUP CORPORATION
    Inventor: Tracy Matray
  • Patent number: 12077524
    Abstract: The present invention provides a crystal of 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid having a certain quality that can be used as a drug substance. Specifically, the present invention provides a crystal comprising an equimolar amount of 1-{2-[(3S,4R)-1-[(3R,4R)-1-cyclopentyl-3-fluoro-4-(4-methoxyphenyl)pyrrolidine-3-carbonyl]-4-(methoxymethyl)pyrrolidin-3-yl]-5-(trifluoromethyl)phenyl}piperidine-4-carboxylic acid and phosphoric acid.
    Type: Grant
    Filed: December 27, 2019
    Date of Patent: September 3, 2024
    Assignee: MITSUBISHI TANABE PHARMA CORPORATION
    Inventors: Naoko Ueda, Hiroomi Nagata, Takahiro Yoshida
  • Patent number: 12065513
    Abstract: System for and method of producing a pure starch slurry and alcohol by using combined corn wet and dry milling processes. A simple and lower cost process to obtain starch inside floury endosperm is provided. The starch can be highly purified to meet green technology process needs. The remaining starch inside the corn kernels can be used as feedstock for alcohol production and to produce valuable co-products such as oil and various animal feeds.
    Type: Grant
    Filed: June 16, 2023
    Date of Patent: August 20, 2024
    Assignee: Lee Tech LLC
    Inventor: Chie Ying Lee
  • Patent number: 12059461
    Abstract: The present invention provides methods for making polysaccharide-protein conjugates in which polysaccharides, typically from bacteria, are conjugated to a carrier protein by reductive amination under conditions which improve conjugation reaction consistency, increase consumption of protein during conjugation reaction, generate conjugates of higher molecular weight, and/or reduce the levels of free cyanide in the conjugate reaction product. The polysaccharide-protein conjugates obtained using these methods are useful for inclusion in multivalent vaccines.
    Type: Grant
    Filed: November 10, 2021
    Date of Patent: August 13, 2024
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jitin Bajaj, Michael Albert Winters, Emily Wen, Jian He
  • Patent number: 12060552
    Abstract: The present invention relates to a new apparatus and a new method for the purification and the recovery of extra-chromosomal nucleic acids sequence(s).
    Type: Grant
    Filed: July 4, 2019
    Date of Patent: August 13, 2024
    Assignee: KANEKA EUROGENTEC S.A.
    Inventor: Laurent Jost
  • Patent number: 12055553
    Abstract: Methods of detecting altered HDL functionality as well as adjusting HDL functionality are described.
    Type: Grant
    Filed: March 9, 2018
    Date of Patent: August 6, 2024
    Assignee: The Regents of the University of California
    Inventors: Angela Zivkovic, Carlito B. Lebrilla, Emanual Maverakis